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ABSTRACT
Objectives Despite the therapeutic value of current
rheumatoid arthritis (RA) treatments, agents with
alternative modes of action are required. Mavrilimumab,
a fully human monoclonal antibody targeting the
granulocyte–macrophage colony-stimulating factor
receptor-α, was evaluated in patients with moderate-to-
severe RA.
Methods In a phase IIb study (NCT01706926),
patients with inadequate response to ≥1 synthetic
disease-modifying antirheumatic drug(s), Disease Activity
Score 28 (DAS28)−C reactive protein (CRP)/erythrocyte
sedimentation rate ≥3.2, ≥4 swollen joints despite
methotrexate (MTX) were randomised 1:1:1:1 to
subcutaneous mavrilimumab (150, 100, 30 mg), or
placebo every other week (eow), plus MTX for 24 weeks.
Coprimary outcomes were DAS28−CRP change from
baseline to week 12 and American College of
Rheumatology (ACR) 20 response rate (week 24).
Results 326 patients were randomised (150 mg, n=79;
100 mg, n=85; 30 mg, n=81; placebo, n=81); 305
completed the study (September 2012–June 2013).
Mavrilimumab treatment signiﬁcantly reduced DAS28
−CRP scores from baseline compared with placebo
(change from baseline (SE); 150 mg: −1.90 (0.14),
100 mg: −1.64 (0.13), 30 mg: −1.37 (0.14), placebo:
−0.68 (0.14); p<0.001; all dosages compared with
placebo).
Signiﬁcantly more mavrilimumab-treated patients
achieved ACR20 compared with placebo (week 24:
73.4%, 61.2%, 50.6% vs 24.7%, respectively
(p<0.001)). Adverse events were reported in 43
(54.4%), 36 (42.4%), 41 (50.6%) and 38 (46.9%)
patients in the mavrilimumab 150, 100, 30 mg eow and
placebo groups, respectively. No treatment-related safety
signals were identiﬁed.
Conclusions Mavrilimumab signiﬁcantly decreased RA
disease activity, with clinically meaningful responses
observed 1 week after treatment initiation, representing
a novel mechanism of action with persuasive therapeutic
potential.
Trial registration number NCT01706926; results.
INTRODUCTION
Biological therapies have improved disease control
and patient outcomes in rheumatoid arthritis (RA).
However, approximately 50% of patients do not
achieve low disease activity criteria within
12 months of antitumour necrosis factor-α treat-
ment,1 while approximately 80% of patients do not
achieve Disease Activity Score 28 (DAS28)
−erythrocyte sedimentation rate (ESR)<2.6.2 It is
possible that biologics targeting novel signalling
pathways may prove beneﬁcial in RA, including in
these patients.
Recently, granulocyte–macrophage colony-
stimulating factor (GM−CSF), a proinﬂammatory
multifunctional cytokine, has emerged as a novel
and important therapeutic target in autoimmune/
inﬂammatory diseases.3 In RA pathogenesis, GM
−CSF plays a key role through activation, differen-
tiation and survival of macrophages, dendritic cells
and neutrophils.4–6 In addition, GM–CSF is now
well recognised as an effector T helper 1/17 cell
cytokine.3 7 Elevated concentrations of GM−CSF
and its receptor have been observed in tissue and
synovial ﬂuid of patients with RA,8–10 and recom-
binant GM−CSF administration exacerbates RA
disease activity.11 Moreover, signalling through the
GM−CSF receptor-α subunit (GM−CSFR-α) has
been shown to have a role in animal models of arth-
ritis10 12 and modulation of pain pathways.13
Inhibition of the GM−CSF pathway reduces macro-
phage and/or neutrophil numbers in inﬂammatory
lesions.14 This treatment approach may hold promise
in RA and other diseases characterised by the activa-
tion of the monocyte–macrophage pathway. In
humans, full inhibition of GM−CSF signalling, via
emergence of GM–CSF neutralising polyclonal auto-
antibodies, has been associated with the development
of foamy alveolar macrophages, and, clinically, with
a lung disorder, pulmonary alveolar proteinosis
(PAP).15
Mavrilimumab, a fully human monoclonal anti-
body which blocks the GM−CSF receptor, is the
ﬁrst biologic in clinical development to target this
pathway. Clinical studies demonstrated the pharma-
cokinetics, pharmacodynamics and safety/tolerability
of mavrilimumab, and provided evidence of efﬁ-
cacy.16–20 In this longer 24-week phase IIb study,
we evaluated the therapeutic potential of GM−CSF
antagonism in patients with moderate-to-severe,
adult-onset RA by comparing the efﬁcacy and
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safety/tolerability of subcutaneous mavrilimumab, at dosages of
up to 150 mg every other week (eow) plus methotrexate
(MTX), with that of placebo.
METHODS
Study design
This phase IIb, randomised, double-blind, parallel-group,
placebo-controlled study (EARTH EXPLORER 1;
NCT01706926) was conducted in 48 specialist sites (14 coun-
tries; Europe, South America, South Africa) (see online
supplementary table S1). Population pharmacokinetic efﬁcacy
modelling and stochastic clinical trial simulations facilitated
selection of the optimal dose range for the study.
Due to the theoretical risk associated with GM−CSF inhib-
ition and data from non-clinical (animal toxicology) studies of
mavrilimumab,21 standardised pulmonary monitoring with inde-
pendent expert adjudication was undertaken.22
The study was conducted in accordance with the principles
of the Declaration of Helsinki and the International Conference
on Harmonisation Guidance for Good Clinical Practice and
approved by appropriate institutional review boards or inde-
pendent ethics committees at each site.
Patients
Patients were 18–80 years with moderate-to-severe, adult-onset
RA,23 DAS28−C reactive protein (CRP) ≥3.2 at screening
and DAS28−ESR ≥3.2 at day 1,24 and ≥4 swollen joints at
screening and day 1, and were receiving stable dosages of MTX
(7.5–25.0 mg/week). Patients were required to have received
treatment with ≥1 traditional disease-modifying antirheumatic
drug (DMARD) prior to screening. Previous treatment with any
biological DMARD discontinued because of lack of efﬁcacy;
recent treatment with any investigational drug, alkylating agents
or parenteral steroids; and concurrent treatment with DMARDs
other than MTX were not permitted. Changes in background
RA treatment were not allowed for the ﬁrst 12 weeks of the
study, other than for safety reasons. Patients with clinically
uncontrolled respiratory disease, active infection or high infec-
tion risk, and active or untreated latent tuberculosis were
excluded. All patients provided written informed consent and
were enrolled by the investigator or qualiﬁed designee.
Study-stopping criteria are listed in the online supplementary
material.
Randomisation and masking
Patients were randomised (interactive web response system)
1:1:1:1 to 150, 100 or 30 mg subcutaneous mavrilimumab or
placebo eow in combination with stable dosages of MTX (7.5–
25.0 mg/week) for 24 weeks, followed by transfer to a long-
term, open-label extension (OLE) (NCT01712399) or a
12-week safety follow-up period. Study patients, investigators
and sponsors were blinded to study treatment (see online
supplementary material).
Procedures
During the 24-week treatment period, there were 14 scheduled
visits (weeks 0, 1, 2 and eow until week 24). The safety
follow-up period included visits at 4, 8 and 12 weeks after the
last dose. Twelve weeks after treatment initiation, patients
without adequate response (<20% improvement in both
swollen and tender joint counts vs day 1) were eligible for early
OLE entry. Corticosteroids (≤7.5 mg/day prednisolone or
equivalent), analgesics and non-steroidal anti-inﬂammatory
drugs were maintained at stable dosages for the study duration.
End points
Primary end points
Coprimary end points were change from baseline in DAS28
−CRP score (week 12) and American College of Rheumatology
(ACR) 20 (20% improvement in ACR criteria) response (week
24). Assessments performed are included in the online
supplementary material.
Secondary end points
Secondary efﬁcacy end points included: DAS28−CRP European
League Against Rheumatism (EULAR) response rates, DAS28
−CRP-deﬁned remission (<2.6) and low disease activity (<3.2),
ACR20/50/70 response rates at weeks 12 and 24, change from
baseline or geometric means for ACR and DAS28 components
over time and DAS28−ESR response. Assessments were per-
formed at weeks 0, 1, 2, 4, 8, 12, 16, 20 and 24.
CRP and ESR geometric means were measured over time.
Exploratory end points
Exploratory end points, including disease activity and structural
damage biomarkers, were examined at weeks 0, 1, 2, 4, 12 and
24. Multibiomarker disease activity (MBDA) Vectra DA score
(Crescendo Biosciences, South San Francisco, California, USA)25
was calculated to track the effects of mavrilimumab on inﬂam-
matory biomarkers at predeﬁned time points.
An ELISA was used to measure serum concentrations of
C1M,26 a marker of tissue damage associated with structural
progression.27
Safety assessments
Adverse events (AEs) and serious adverse events (SAEs) were
summarised by severity and relationship to study drug by inves-
tigators. Laboratory evaluations (serum chemistry, haematology,
urinalysis), vital signs, pulmonary function tests (PFTs), dys-
pnoea score and oxygen saturation were summarised by treat-
ment group and time point. Serum was tested for antidrug
antibodies (ADAs) and mavrilimumab concentrations through-
out the study. Safety assessments were performed at every visit
during the treatment period.
PFTs (forced vital capacity, forced expiratory volume in 1 and
6 s) were performed at screening, and at weeks 12 and 24.
Dyspnoea score and oxygen saturation were assessed at each
visit using the modiﬁed Borg scale and pulse oximetry, respect-
ively. Adjudication of lung function abnormalities and pulmon-
ary AEs was by an Independent Pulmonary Expert Committee.
Statistical analysis
The primary efﬁcacy population was the modiﬁed
intention-to-treat population (all randomised patients who
received any study drug). The safety population included all
patients who received study drug and had safety data available.
A sample size of 70 patients per treatment group provided
80% power to achieve statistical signiﬁcance for DAS28−CRP
and ACR20 at a two-sided signiﬁcance level of 0.05. This
assumed a 0.6-unit difference in change from baseline and a SD
of 1.25 for DAS28−CRP, and a 25% difference in ACR20
response rate with a placebo response rate of 40%.
Change from baseline in DAS28−CRP was analysed using a
mixed model for repeated measures (MMRM), with covariates
for baseline DAS28−CRP, visit, treatment and visit-by-treatment
interaction. Dosage–response assessment was performed using a
test for linear trend on DAS28−CRP change from baseline at
week 12. Two sensitivity analyses were performed for change
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from baseline DAS28−CRP to allow for patients withdrawing
from treatment (see online supplementary material). ACR20/50/
70 response rates, DAS28-deﬁned remission (<2.6) and
response rates at each visit were analysed using logistic regres-
sion, with results presented as differences in response rates
(95% CI; p value).28 Individual ACR components were analysed
using the same method as for DAS28−CRP analyses.
DAS28−CRP EULAR responses at each time point were ana-
lysed via a proportional odds model, with treatment as a factor.
CRP and ESR were log-transformed prior to analysis. For dis-
crete responder outcomes, patients who withdrew from treat-
ment for any reason (including entering the OLE), started any
new RA medication, or increased MTX dosage, were imputed
as non-responders for all subsequent assessments. For continu-
ous outcomes (DAS28−CRP and ACR components), missing
data were handled by the MMRM analysis (including patients
entering the OLE). For MBDA and C1M, results for each time
point were analysed versus placebo using a non-parametric
Mann-Whitney U test. AE and other safety data were sum-
marised with descriptive statistics. An external independent
safety data monitoring board oversaw the study.
RESULTS
Patients were recruited between September 2012 and June
2013, with evaluation until January 2014. Of 326 patients ran-
domised, 305 (93.6%) completed the study. Patient disposition
is presented in ﬁgure 1. Demographics and baseline clinical
characteristics were similar between treatment groups, and indi-
cated a cohort of patients with predominantly severe disease
(DAS28−CRP >5.1) that would qualify for ﬁrst-line biological
therapy (see table 1 and online supplementary table S2).
Mavrilimumab signiﬁcantly reduced DAS28−CRP scores from
baseline compared with placebo at week 12, meeting the
coprimary outcome (change from baseline (difference from
placebo (95% CI)) 150 mg: −1.90 (−1.22 (−1.60 to −0.84)),
100 mg: −1.64 (−0.96 (−1.33 to −0.58)), 30 mg: −1.37 (−0.69
(−1.06 to −0.31)), placebo: −0.68; p<0.001, all dosages;
ﬁgure 2A). Differences from placebo were detected at week 1,
with treatment beneﬁt increasing through week 12 (ﬁgure 2A).
At week 24, signiﬁcantly more patients receiving mavrilimumab
150 mg eow achieved an ACR20 response compared with
placebo, with a dosage-dependent response (150 mg: 73.4%;
100 mg: 61.2%; 30 mg: 50.6%; placebo: 24.7% (p<0.001);
ﬁgure 2B), indicating that the study also met its second coprim-
ary outcome. There were signiﬁcantly more ACR20 responders
in the mavrilimumab 150 mg eow group than in the placebo
group from the ﬁrst assessment (week 1) and at every other
assessment through to week 24 (ﬁgure 2B). Subgroup analyses
of ACR20 by CRP concentration (normal or greater than the
upper limit of normal), the presence of rheumatoid factor and/
or anticitrullinated protein antibody (ACPA), and prior use of
biologics and smoking status (see online supplementary table
S3) suggest that clinical response is not dependent on baseline
disease characteristics. Furthermore, mavrilimumab was demon-
strated to be efﬁcacious in patients who were rheumatoid factor
negative and ACPA-negative at baseline (n=59; 18.1%).
DAS28−CRP/ESR EULAR good and moderate responses
occurred more frequently with mavrilimumab 150, 100 and
30 mg eow than placebo at weeks 12 and 24 (ﬁgure 3). This
was also true for ACR20 and ACR50 response rates (ACR50
response at week 24: 40.5%, 25.9%, 28.4% and 12.3%,
respectively; p<0.05, all dosages; ﬁgure 3). Mavrilimumab
150 mg eow signiﬁcantly improved ACR70 response rates
compared with placebo at weeks 12 and 24 (week 12: 10.1% vs
1.2% (p=0.017); week 24: 13.9% vs 3.7% (p=0.026);
ﬁgure 3). At week 24, there was a signiﬁcantly greater ACRn
response for patients receiving mavrilimumab compared with
placebo (ﬁgure 3). Rates of DAS28−CRP remission (<2.6) were
also signiﬁcantly greater with mavrilimumab 150 mg compared
with placebo at week 12 and all dosages of mavrilimumab com-
pared with placebo at week 24 (p<0.05, all dosages; ﬁgure 3).
There were signiﬁcantly more patients with DAS28−CRP low
disease activity scores (<3.2) in the mavrilimumab 150 mg eow
group compared with placebo at weeks 12, 16, 20, 24 (31.6%,
40.5%, 43.0%, 41.8% vs 12.3%, 14.8%, 14.8%, 8.6%, respect-
ively) and in all mavrilimumab groups compared with placebo
at week 24 (p<0.001; ﬁgure 3). To conﬁrm the robustness of
the data, analyses of change from baseline in DAS28−ESR were
also performed, and results were similar to those using DAS28
−CRP (see online supplementary ﬁgure S1).
Results for components of composite outcomes were similar.
Greater changes from baseline in ACR and DAS28 components,
and patient-reported outcomes compared with placebo were
observed at weeks 12 and 24 for patients receiving mavrilimu-
mab 150 mg eow (see online supplementary table S4). As a
greater number of patients in the placebo group than in the
mavrilimumab group transferred to the OLE study between
weeks 12 and 24 because of lack of response under ‘rescue’ cri-
teria, it is important to interpret the week 24 data with caution.
A dosage-dependent, rapid (week 1) and sustained (week 24)
reduction of both CRP and ESR concentrations was also
observed, with CRP levels plateauing at approximately 3.3 mg/L
(see ﬁgure 4A and online supplementary ﬁgure S2, respectively).
Of 326 patients, 120 reported at least one AE (150 mg: 43
(54.4%); 100 mg: 36 (42.4%); 30 mg: 41 (50.6%); placebo: 38
(46.9%)). The most common treatment-emergent AEs (TEAEs),
and those leading to discontinuation or interruption of the
study drug, are provided in table 2. SAEs were reported for two
(2.5%), ﬁve (5.9%), four (4.9%) and one (1.2%) patients in the
mavrilimumab 150, 100, 30 mg eow and placebo groups,
respectively (table 2). Of these, only pneumonia (mavrilimumab
30 mg eow) and angioedema (mavrilimumab 150 mg eow) were
considered to be related to treatment by the investigator.
Rates of pulmonary AEs for mavrilimumab 150, 100 or 30 mg
eow were similar to the rate for placebo (6.3%, 3.5%, 6.2% vs
9.9%, respectively). There were no deaths or anaphylaxis. Two
hypersensitivity AEs led to discontinuation (angioedema 6 days
after ﬁrst dose, mavrilimumab 150 mg eow; drug hypersensitiv-
ity 1 day after ﬁrst dose, mavrilimumab 30 mg eow).
No clinically meaningful differences between mavrilimumab-
treated and placebo-treated patients in haematology, including
neutrophils, serum chemistry and urinalysis parameters, were
observed. ADAs were detected in 0 (0.0%), 3 (3.5%), 13
(16.0%) and 2 (2.5%) patients in the mavrilimumab 150, 100,
30 mg eow and placebo groups, respectively (see online
supplementary material). One injection-site reaction was
observed (mavrilimumab 150 mg eow).
Pulmonary function values, dyspnoea scores and oxygen sat-
uration were generally similar between mavrilimumab-treated
and placebo-treated patients, with no evidence of a dosage-
dependent decline in the mean values for patients receiving
mavrilimumab (see online supplementary table S5). Any thresh-
old changes in the percentage of PFT values were generally
transient.
In biomarker analyses, treatment with mavrilimumab 150 and
100 mg eow induced early (week 1) and sustained (week 24)
signiﬁcant reductions in MBDA score versus placebo (p<0.01;
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Figure 1 CONSORT diagram (A) and time to randomised study exit (B). Randomised study exit includes patients who withdrew from study
treatment, patients who entered the OLE from week 12 as permitted in the protocol and those patients who entered the safety follow-up period at
week 24. At week 12, 3 (3.8%), 8 (9.4%), 12 (14.8%) and 37 (45.7%) patients transferred to the OLE study because of lack of efﬁcacy in the
mavrilimumab 150, 100 and 30 mg groups and placebo group, respectively. eow, every other week; OLE, open-label extension.
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ﬁgure 4B). Signiﬁcant decreases from baseline in C1M concen-
trations were also observed for patients receiving mavrilimumab
150 and 100 mg eow compared with placebo from week 1 to
week 24 (p<0.01; ﬁgure 4C).
DISCUSSION
This phase IIb study met its coprimary outcomes, with mavrili-
mumab treatment resulting in dosage-related, signiﬁcantly
greater reductions from baseline in DAS28−CRP scores at week
12 and a signiﬁcantly greater percentage of ACR20 responders
at week 24, compared with placebo. The most effective dose
was 150 mg eow. Mavrilimumab-treated patients also demon-
strated signiﬁcantly greater improvements than those receiving
placebo across a range of secondary and patient-reported out-
comes29 (see online supplementary table S4). The data pre-
sented here are consistent with and build on those presented
previously for mavrilimumab 100 mg by including a larger
patient population, longer treatment duration and the higher
(150 mg) mavrilimumab dosage.19 20
A rapid and sustained clinical response to mavrilimumab 150
and 100 mg eow was reﬂected in the reduction of CRP and
ESR, concurrent decreases in MBDA score, a composite of
soluble disease activity biomarkers and C1M concentration.27
A clear dosage–response relationship was observed for
mavrilimumab-treated patients in most efﬁcacy outcomes ana-
lysed and for biomarker analyses, but not in AE rates or other
Table 1 Patient demographics and baseline clinical characteristics
Mavrilimumab
150 mg eow (n=79) 100 mg eow (n=85) 30 mg eow (n=81) Placebo (n=81)
Demographics
Age, mean (SD) 52.6 (10.3) 50.8 (11.9) 51.2 (11.6) 52.8 (10.6)
Female, n (%) 67 (84.8) 70 (82.4) 70 (86.4) 75 (92.6)
Race, n (%)
White 74 (93.7) 81 (95.3) 76 (93.8) 76 (93.8)
Other 5 (6.3) 4 (4.7) 5 (6.2) 5 (6.2)
Weight, kg, mean (SD) 75.9 (17.6) 71.8 (16.2) 72.5 (15.2) 73.0 (15.2)
Body mass index, kg/m2, mean (SD) 28.4 (6.2) 26.3 (5.3) 27.3 (5.1) 27.5 (5.1)
Baseline clinical characteristics
Years since RA diagnosis, mean (SD) 8.5 (6.9) 7.2 (6.5) 7.8 (6.6) 7.6 (7.2)
Rheumatoid factor-positive, n (%) 60 (75.9) 68 (80.0) 67 (82.7) 65 (80.2)
ACPA-positive, n (%) 61 (77.2) 63 (74.1) 66 (81.5) 59 (72.8)
DAS28−CRP, mean (SD) 5.7 (0.8) 5.9 (0.9) 5.7 (0.9) 5.8 (0.8)
DAS28−ESR, mean (SD) 6.5 (0.9) 6.7 (0.9) 6.7 (1.0) 6.6 (0.9)
Swollen joint count, mean (SD) 15.7 (7.1) 16.8 (8.6) 17.8 (10.1) 14.4 (6.9)
Tender joint count, mean (SD) 26.7 (11.4) 27.0 (14.2) 27.5 (14.0) 26.3 (11.3)
HAQ DI, mean (SD) 1.58 (0.53) 1.58 (0.52) 1.52 (0.62) 1.63 (0.48)
CRP, mg/L, median (minimum–maximum) 5.6 (0.3–55.8) 9.0 (0.3–75.3) 5.2 (0.2–102.8) 6.3 (0.2–110.2)
Normal, n (%) 27 (34.2) 22 (25.9) 32 (39.5) 24 (29.6)
Greater than ULN, n (%)* 52 (65.8) 63 (74.1) 49 (60.5) 57 (70.4)
ESR, mm/hour, median (minimum–maximum) 38.0 (8–101) 40.0 (6–123) 40.0 (6–110) 42.0 (3–112)
MBDA score, mean (SD) 50.2 (14.0) 54.2 (16.7) 48.5 (17.3) 50.6 (17.9)
C1M, ng/mL, mean (SD) 83.7 (54.8) 107.1 (76.3) 88.6 (81.3) 98.1 (72.1)
Methotrexate use, n 79 84† 81 81
Dosage, mg/week, mean (SD) 14.5 (4.1) 15.1 (4.6) 14.6 (3.6) 15.0 (3.7)
<12.5 mg/week, n (%) 21 (26.6) 22 (26.2) 19 (23.5) 16 (19.8)
≥12.5 to <20 mg/week, n (%) 44 (55.7) 39 (46.4) 47 (58.0) 51 (63.0)
≥20 mg/week, n (%) 14 (17.7) 23 (27.4) 15 (18.5) 14 (17.3)
Corticosteroid use, n 46 51 50 43
Dosage, mg/day, mean (SD) 5.4 (1.7) 5.7 (1.3) 5.4 (2.4) 5.3 (1.7)
<5 mg/day 5 (10.9) 1 (2.0) 5 (10.0) 6 (14.0)
≥5 mg/day 41 (89.1) 50 (98.0) 45 (90.0) 37 (86.0)
Prior biological therapy, n (%) 10 (12.7) 13 (15.3) 12 (14.8) 12 (14.8)
Reason for discontinuation, n (%)
Expense of medication 2 (2.5) 2 (2.4) 1 (1.2) 1 (1.2)
Medication only in clinical trial 7 (8.9) 9 (10.6) 8 (9.9) 8 (9.9)
Adverse event 0 (0.0) 1 (1.2) 3 (3.7) 1 (1.2)
Other 1 (1.3) 1 (1.2) 0 (0.0) 2 (2.5)
*The upper limit of normal for CRP (high sensitivity) was 3 mg/L.
†One patient did not receive methotrexate (not identified until after randomisation), and this was considered a protocol violation.
ACPA, anticitrullinated protein antibody; CRP, C reactive protein; DAS28, Disease Activity Score 28; eow, every other week; ESR, erythrocyte sedimentation rate; HAQ DI, Health
Assessment Questionnaire Disability Index; MBDA, multibiomarker disease activity; RA, rheumatoid arthritis; SD, standard deviation; ULN, upper limit of normal.
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safety parameters. However, as the study was powered speciﬁc-
ally to assess the coprimary end points, the sample size and
study duration were not sufﬁcient to assess joint damage
progression.
The number of patients who transferred to the OLE between
weeks 12 and 24 because of lack of response was low in the
mavrilimumab 150, 100 and 30 mg eow groups compared with
placebo (3 (3.8%), 8 (9.4%), 12 (14.8%) and 37 (45.7%),
respectively). This could be seen as an indication of the beneﬁt
of mavrilimumab treatment; however, it is a limitation of the
study analysis, as the response of these patients at week 24, had
they remained in the study, is unknown. To account for patients
transferring to the OLE, a non-responder imputation for the
ACR outcomes and a sensitivity analysis for DAS28−CRP were
performed. The primary analysis method of MMRM resulted
in a smaller difference from placebo than both the Last
Observation Carried Forward (LOCF) and the Baseline
Observation Carried Forward (BOCF) method (DAS28−CRP
week 24 mavrilimumab 150 mg eow difference from placebo:
MMRM=−1.21; LOCF=−1.46; BOCF=−1.37).
Mavrilimumab was generally well tolerated, with no substan-
tial differences in AEs or SAEs between mavrilimumab-treated
Figure 2 Changes from baseline in DAS28−CRP score (A), ACR20 response (B) and changes from baseline in patient assessment of pain (C) by
visit. *p<0.05, **p<0.01, ***p<0.001 mavrilimumab versus placebo. ACR, American College of Rheumatology; DAS28−CRP, Disease Activity Score
28–C reactive protein; eow, every other week; SE, standard error.
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and placebo-treated patients (table 2). The percentage of patients
experiencing TEAEs and TEAEs of special interest were similar
in mavrilimumab versus placebo groups. The rate of serious
infection was low (one serious pneumonia (mavrilimumab
30 mg) and one non-serious pneumonia (placebo)). Neutropenia
was reported in three patients in the mavrilimumab 150 mg
Figure 3 Analysis of secondary efﬁcacy outcomes: ACR response rates (A), ACRn response over time (B), DAS28−CRP low disease activity
responders (DAS28−CRP <3.2) (C), DAS28−CRP remission (DAS28−CRP <2.6) over time (D), DAS28−CRP European League Against Rheumatism
(EULAR) response (E), DAS28−ESR EULAR response (F). ACR/EULAR response criteria are detailed in online supplementary table S6. DAS28−CRP
remission deﬁned as DAS28−CRP <2.6. DAS28−CRP low disease activity deﬁned as DAS28−CRP <3.2. ACR, American College of Rheumatology;
DAS28−CRP, Disease Activity Score 28–C reactive protein; ESR, erythrocyte sedimentation rate; eow, every other week; SE, standard error.
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Figure 4 Adjusted geometric mean ratio to baseline in CRP concentrations (A), change from baseline in MBDA score (B) and C1M (C). *p<0.05,
**p<0.01, ***p<0.001 mavrilimumab versus placebo. For MBDA analyses (graph A), the number of patients for whom serum samples were
analysed at each time point ranged from 57 to 64, 53 to 60, 53 to 61 and 40 to 59 for mavrilimumab 150, 100, 30 mg eow and placebo,
respectively. For C1M analyses (graph B), the number of patients for whom serum samples were analysed at each time point ranged from 73 to 76,
74 to 84, 62 to 78 and 54 to 77 for mavrilimumab 150, 100, 30 mg eow and placebo, respectively. CRP, C reactive protein; eow, every other week;
MBDA, multibiomarker disease activity; SE, standard error; ULN, upper limit of normal.
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group (grades 1, 2 and 3) and one patient in the placebo group
(grade 3). ADAs were detected more frequently in patients
treated with lower mavrilimumab dosages and none at the
150 mg dosage, consistent with the previous observations that
development of ADAs is inversely associated with dose.30 31 The
safety proﬁle for mavrilimumab observed in this study was
similar to that reported in previous mavrilimumab studies17 19
and emerging data with other GM−CSF pathway inhibitors.32
No substantial increase in pulmonary events, or apparent
dosage–response changes in pulmonary function, dyspnoea
score or oxygen saturation, was noted for mavrilimumab-treated
patients compared with those receiving placebo. Furthermore,
mavrilimumab treatment was not associated with any conﬁrmed
or suspected case of PAP, as veriﬁed by an Independent
Pulmonary Expert Committee. An open-label, phase II safety
study (NCT01712399) aims to establish the long-term safety and
efﬁcacy proﬁle of mavrilimumab 100 mg in patients with RA.
Despite the success of the currently available biologics in RA,
a considerable percentage of patients do not achieve long-term
responses to these therapies.33 Consequently, new treatments
employing different mechanisms of action from those currently
available, such as GM−CSFR antagonism, are needed. Data
from this study demonstrate that mavrilimumab, particularly at
a dosage of 150 mg eow, provides a rapid, effective and well-
tolerated potential treatment for patients with RA. Moreover,
blockade of GM−CSF signalling could be applicable to patients
for whom treatment with biologics targeting other pathways has
failed or to those with other inﬂammatory/autoimmune dis-
eases.33 This proof-of-concept study conﬁrms that inhibition of
GM−CSF activity is a promising and novel therapeutic approach
for patients with RA, including those who do not adequately
respond to currently available therapies.
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Table 2 Treatment-emergent adverse events occurring in ≥3% of patients in any group and all serious adverse events
Mavrilimumab
Event, n (%)
150 mg eow
(n=79)
100 mg eow
(n=85)
30 mg eow
(n=81)
Placebo
(n=81)
Treatment-emergent adverse events (≥3% patients in any group)
Headache 6 (7.6) 4 (4.7) 5 (6.2) 2 (2.5)
Nasopharyngitis 6 (7.6) 3 (3.5) 4 (4.9) 6 (7.4)
Hypertension 3 (3.8) 4 (4.7) 4 (4.9) 2 (2.5)
Bronchitis 4 (5.1) 1 (1.2) 3 (3.7) 6 (7.4)
Hyperlipidaemia 3 (3.8) 0 (0.0) 2 (2.5) 0 (0.0)
Influenza 1 (1.3) 3 (3.5) 1 (1.2) 0 (0.0)
Rheumatoid arthritis 0 (0.0) 2 (2.4) 2 (2.5) 4 (4.9)
Neutropenia* 3 (3.8) 0 (0.0) 0 (0.0) 1 (1.2)
Treatment-emergent serious adverse events
Atrial tachycardia 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0)
Supraventricular tachycardia 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0)
Dyspepsia 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0)
Cholelithiasis 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0)
Pneumonia† 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0)
Lower limb fracture 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0)
Tendon rupture 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0)
Osteoarthritis 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0)
Rheumatoid arthritis 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.2)
Adenocarcinoma of the cervix 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0)
Squamous cell carcinoma of the
lung
1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)
Cystocele 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0)
Angioedema 1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)
Treatment-emergent adverse events resulting in permanent discontinuation of the study drug
Patients reporting ≥1 event 5 (6.3) 3 (3.5) 3 (3.7) 2 (2.5)
Treatment-emergent adverse events resulting in interruption of the study drug
Patients reporting ≥1 event 2 (2.5) 10 (11.8) 8 (9.9) 9 (11.1)
Treatment-emergent adverse events considered to be treatment-related
17 (21.5) 8 (9.4) 10 (12.3) 6 (7.4)
Treatment-emergent adverse events of special interest
Patients reporting ≥1 event 11 (13.9) 5 (5.9) 7 (8.6) 10 (12.3)
*Grade 3 (placebo); grades 1, 2 and 3 (mavrilimumab 150 mg).
†One non-serious pneumonia was reported in the placebo group.
eow, every other week.
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